The Nalitt Institute has an established Bone Marrow Transplantation Program that provides another major clinical program that has brought it national recognition as a progressive cancer detection and treatment facility.
Directing the bone marrow transplantation program is Charles Zaroulis, M.D., who has made significant contributions to research in blood diseases and stem cell, as well as marrow collection and preservation. This stem cell and marrow transplantation program allows the Nalitt's accomplished team of cancer specialists an alternative therapy for patients, and provides for them a remarkable mix of comprehensive and custom-tailored care coupled with state-of-the-art technology.
Transplanting bone marrow in a cancer patient with a variety of malignancies is an increasingly recognized treatment that can lead to a patient's prolonged remission from the disease. Dr. Zaroulis follows proven clinical chemotherapeutic protocols to treat patients with lymphoma, leukemia, ovarian cancer, multiple myeloma, and breast cancer, usually found in younger patients. Research and experience indicate that marrow transplants may be highly effective in halting the progression of cancer in some patients.
 | Charles Zaroulis, M.D. Dr. Zaroulis' years of experience in the preservation and transplanting of bone marrow — where the body's blood and immune cells originate — spans Memorial Sloan Kettering Cancer Center, where he helped establish the program, Mount Sinai Medical Center , and the U.S. Naval Blood Research Laboratory, Boston, where, he still plays an active and significant role. He matches the depth of his knowledge with an abiding and genuine concern for his patients. |